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Abstract: Hereditary non-polyposis colorectal cancer (HNPCC) is associated with germline mutations
in DNA mismatch repair genes, predominantly MSH2 and MLH1. Mutation carriers develop can-
cers in the colorectum, endometrium, ovary, stomach, small intestine and the upper urinary tract.
We describe here the results of a mutational analysis of 11 unrelated HNPCC patients by direct ge-
nomic sequencing of MLH1 and MSH2. The alterations found include 7 novel changes and 4 differ-
ent pathogenic mutations described previously in Poland, Moldavia, Finland, Germany, France and
USA. Four novel pathogenic mutations in the MLH1 gene include two frameshift mutations (c.1150delG
and c.12101211delCT ), onemissensemutation(c.793C > A)andoneintron−exonbordermutation(c.546−
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Hereditary non-polyposis colorectal cancer (HNPCC) is associated with germline mutations in DNA mismatch repair
genes, predominantly MSH2 and MLH1. Mutation carriers develop cancers in the colorectum, endometrium, ovary, stom-
ach, small intestine and the upper urinary tract. We describe here the results of a mutational analysis of 11 unrelated HNPCC
patients by direct genomic sequencing of MLH1 and MSH2. The alterations found include 7 novel changes and 4 different
pathogenic mutations described previously in Poland, Moldavia, Finland, Germany, France and USA. Four novel patho-
genic mutations in the MLH1 gene include two frameshift mutations (c.1150delG and c.1210_1211delCT), one missense
mutation (c.793C>A) and one intron-exon border mutation (c.546-2A>C). The last change resulted in the skipping of exon
7, as shown by sequencing of RT-PCR products. The only novel MSH2 pathogenic change was a nonsense mutation
c.1129C>T. The novel intronic change c.381-41A>G in MLH1 was found in a patient carrying a previously-described muta-
tion in the MSH2 gene. Interestingly, two unrelated patients carried also a novel change in the promoter region of MLH1 in
one of the CpG islands (c.-269C>G). However, this alteration does not abrogate transcription, as shown by RT-PCR analy-
sis. In summary, most (~80%) pathogenic germline mutations detected in the studied group of patients by direct genomic se-
quencing of MLH1 and MSH2 were located in the MLH1 gene. These and previous data indicate that the majority of
germline point mutations and small deletions/insertions in HNPCC families in Slovakia affect the MLH1 locus.
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During recent years, molecular diagnostic methods for
several hereditary cancer syndromes were established in the
Slovak Republic, with the ultimate goal of reducing cancer
mortality through early identification of at-risk individuals
and effective prophylaxis [1–7]. Much of our attention is
dedicated to hereditary non-polyposis colorectal cancer
(HNPCC), the most common familial colorectal cancer
(CRC) syndrome, which accounts for ~4% of all CRC cases
[8]. In Slovakia, where about 2600 CRC cases are diagnosed
annually with the incidence of 58.7 per 100 000 inhabitants
[9], this translates to ~80 HNPCC cases per annum.
HNPCC (MIM#114500), also called the Lynch syndrome,
is an autosomal dominant disease with high penetrance
(85%) and younger age of onset when compared to patients
with sporadic tumors. Although Lynch syndrome patients are
primarily afflicted with cancers of the colon and endo-
metrium, the tumor spectrum of HNPCC includes also ovar-
ian, gastric and brain tumors, as well as cancer of the small
bowel, hepatobiliary tract and upper urologic tract [10].
Lynch syndrome is associated with germline mutations in
DNA mismatch repair (MMR) genes (see [11] for a recent re-
view). According to InSIGHT (International Society for
Gastrointestinal Hereditary Tumors) database, approxi-
mately 50 and 40% of the HNPCC-causing mutations are
found in the MLH1 (MIM#120436; GDB: 249617) and
MSH2 (MIM#120435; GDB: 203983) genes, respectively,
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with mutations in MSH6, MSH3, PMS1 and PMS2 compris-
ing the remaining 10%. Accordingly, recent strategies of mu-
tation detection focus primarily on MLH1 and MSH2 [12,
13, 14].
Despite substantial advances in our understanding of
HNPCC, much remains to be learned about the correlations
between the genetic changes and clinical features of the dis-
ease. Description of novel or recurrent alterations of MMR
genes in clinically well defined HNPCC families has the po-
tential to reveal new properties of the disease, mechanisms of
pathogenicity and links to new biological pathways, which
may turn out to be useful in the design of preventive and ther-
apeutic strategies in the future. The aim of this study is to de-
scribe the novel and recurrent mutations of clinically well de-
fined HNPCC families identified during DNA sequencing
screening of MLH1 and MSH2 genes. The identification of
pathogenic germline MMR gene mutations is one of the key
prerequisites for the identification of at-risk individuals.
Material and methods
Patients and samples. The study involved 11 families (ten
of Slovak and one of mixed Slovak/Italian [IT/SK-15] ori-
gin). The index patients fulfilled clinical criteria for HNPCC
testing, either the strict Amsterdam criteria (AC-I or AC-II),
or the less-stringent Bethesda guidelines (BG or RBG).
These were recently reviewed by VASEN [15] and are listed in
Table 1. The index cases of these 11 families included 6 fe-
males and 5 males in the age range of 28–52 years (average
age 38 years) at first diagnosis. Samples of peripheral blood
leukocytes were obtained from the patients after informed
consent during the clinico-genetic consultation. From two
patients, additional blood samples were collected using
PAXgene Blood RNA Tubes (Qiagen, Hilden, Germany) for
preservation of RNA and further use in RT-PCR analyses.
The analysis of 100 control chromosomes was performed us-
ing the peripheral blood samples of 50 healthy individuals.
DNA sequencing. Genomic DNA for sequencing was iso-
lated using QIAamp DNA Blood Mini Kit (Qiagen, Hilden,
Germany). The MLH1 gene was divided into 21 fragments
covering the promoter and 19 exons with substantial parts of
intron regions (exon 12 was subdivided in 2 overlapping
fragments). The MSH2 gene was divided into 17 fragments
covering the promoter and 16 exons. The primers (Tab. 2A,
B) were designed such that they could be used with identical
PCR amplification protocols. This allowed a simultaneous
amplification of all PCR fragments and resulted in a signifi-
cant time-saving. Some of the MSH2 gene primers in our set
were identical to those published previously [16]. The PCR
reactions contained 7.5 pmol each primer, 12.5 µl AmpliTaq
Gold PCR Master Mix (Applied Biosystems, Foster City,
USA) and 50 ng DNA in a final reaction volume of 25 µl. The
following cycling conditions were used for all PCRs: initial
denaturation at 95 °C for 10 minutes, followed by 8 cycles of
denaturation at 98 °C for 10 seconds, annealing step at 60 °C
for 30 seconds and extension at 70 °C for 1 minute, followed
by additional 37 cycles of denaturation at 96 °C for 10 sec-
onds and annealing-extension step at 68 °C for 2 minutes. Af-
ter purification by ethanol-sodium acetate method with
PelletPaint NF Co-Precipitant (Novagen, Madison, USA) the
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Table 1. Clinical criteria of Lynch syndrome (HNPCC)
AC-I
There should be at least 3 relatives with colorectal cancer and all criteria must be satisfied:
• One relative should be a first-degree relative of the other two
• At least two successive generations should be affected
• At least one tumor should be diagnosed before the age of 50
• Familial adenomatous polyposis should be excluded
• Tumor should be verified by a histopathological examination
AC-II There should be at least 3 relatives with colorectal cancer or with HNPCC-associated cancer: cancer of the endometrium, small bowel, ureteror renal pelvis and all Amsterdam criteria I must be satisfied.
BG
1. Individuals with two HNPCC-associated cancers, including synchronous and metachronous colorectal cancers or associated extra-colonic
cancers (endometrial, ovarian, gastric, hepatobiliary, small bowel cancer or transitional cell carcinoma of renal pelvis or ureter
2. Individuals with colorectal cancer and a first degree relative with colorectal cancer and/or HNPCC-associated extra-colonic cancer and/or
colorectal adenoma; one of the cancers diagnosed at age <45 years, and the adenoma diagnosed at the age <40
3. Individuals with colorectal cancer or endometrial cancer diagnosed at the age <45
4. Individuals with right-sided colorectal cancer with an undifferentiated pattern on histopathology diagnosed at age <45
5. Individuals with signet-ring-cell-type colorectal cancer diagnosed at age <45
6. Individuals with adenomas diagnosed at age <45
RBG
1. Colorectal cancer diagnosed in a patient at age <50
2. Presence of synchronous, metachronous colorectal, or other HNPCC-associated tumors, regardless of age
3. Colorectal cancer with MSI-H phenotype diagnosed in a patient <60 years of age
4. Individual with colorectal cancer and one or more first-degree relatives with an HNPCC-related tumor, with one of the cancers diagnosed
under the age of 50
5. Individual with colorectal cancer and two or more first-degree or second-degree relatives with HNPCC-associated tumors, regardless of age
AC-I/AC-II – Amsterdam criteria I, II; BG – Bethesda Guidelines; RBG – Revised Bethesda Guidelines
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Table 2A. Primers for the amplification of the genomic regions of MLH1
Region Forward 5’-3’* Reverse 5’-3’* Product length (bp)
Promoter M13F-ACCACCAAATAACGCTGGGTC M13R-AATCACCTCAGTGCCTCGTGC 536
Exon 1 M13F-TGACTGGCATTCAAGCTGTCC M13R-CTGACTGGCACGTCAGGGAAC 470
Exon 2 M13F-TTGGAGTTTGTTATCATTGCTTGG M13R-ACTGACACATCCCCTGAACAGTG 398
Exon 3 M13F-CAAAGAGATTTGGAAAAATGAG M13R-CAAACCTTATTTATCTATGTTGAG 294
Exon 4 M13F-CAGATAACCTTTCCCTTTGGTGAG M13R-TGGTGTTGAGACAGGATTACTCTGAG 281
Exon 5 M13F-TGATATGATTTTCTCTTTTCCCC M13R-GTGCAAATTCATTTTATTATTACCC 300
Exon 6 M13F-CTTTTGCCAGGACATCTTGGG M13R-TTTCACCATCTAGCTCAGCAACTG 302
Exon 7 M13F-TAAAAGGGGGCTCTGACATC M13R-AAACATCATAACCTTATCTCCACC 245
Exon 8 M13F-ATGTTTCAGTCTCAGCCATG M13R-CAAGCCTGTGTATTTGACTAAAG 316
Exon 9 M13F-CAAAGTTAGTTTATGGGAAGGAAC M13R-CATGAGGTTTCTCCATGTTTAATC 372
Exon 10 M13F-TGTCTTTCCTGAGGTGATGTCATG M13R-CCTTTTGCCAGTGGTGTATGGG 359
Exon 11 M13F-GGTTTTGACCACTGTGTCATCTG M13R-AATCTGGGCTCTCACGTCTG 382
Exon 12-I M13F-TACTGCTCCATTTGGGGACCTG M13R-AGCATCTCCTCATCTTGCTGCC 400
Exon 12-II M13F-GGTCTATGCCCACCAGATGG M13R-CATGAAAAGCCAAAGTTAGAAGG 392
Exon 13 M13F-GCTTGCTCCCAAATGCAACC M13R-GCCCATCAAAACTGTAGTGCCAC 380
Exon 14 M13F-TCTAGTTCTGGTGCCTGGTGCTTTG M13R-GCCTGTGCTCCCTGGACCATTG 300
Exon 15 M13F-TCTGTCTCATCCATGTTTCAGGG M13R-CGATCAGTTGAAATTTCAGAAGTG 250
Exon 16 M13F-TCATTTGGATGCTCCGTTAAAG M13R-AATTTTATTTGGAGAATACAACAGAAG 301
Exon 17 M13F-CAGATAGGAGGCACAAGGCCTG M13R-TTGCCCTTTCCCTCCAGCAC 293
Exon 18 M13F-CAGTCCCATTTACAGTTTTAACGCC M13R-TGTCCTAGTCCTGGGGTGCC 323
Exon 19 M13F-AGATAACACCAAGTCTTTCCAGAC M13R-TCAATCCACTGTGTATAAAGGAATAC 474
*Forward primers have M13F tail attached for sequencing: TGTAAAACGACGGCCAGT; Reverse primers have M13R tail attached for sequencing:
CAGGAAACAGCTATGACC
Table 2B. Primers for the amplification of the genomic regions of MSH2
Region Forward 5’-3’* Reverse 5’-3’* Product length (bp)
Promoter M13F-AAATACTGGGAGGAGGAGGAAGG M13R-CACCGCCATGTCGAAACCTC 512
Exon 1 M13F-AAACGCAGCCCTGGAAGCTG M13R-GTGCCTCCGCACTGGAGAGG 494
Exon 2 M13F-GTCCAGCTAATACAGTGCTTG M13R-CACATTTTTATTTTTCTACTCTTAA 316
Exon 3 M13F-AAAGTATGTTCAAGAGTTTGTTAAATTTTT M13R-CTTTCCTAGGCCTGGAATCTC 413
Exon 4 M13F-TTTTTGCTTTTCTTATTCCTTTTC M13R-TGACAGAAATATCCTTCTAA 345
Exon 5 M13F-GTGGTATAGAAATCTTCGATTTTT M13R-AATCAACATTTTTAACCCTTTT 273
Exon 6 M13F-TTTTCACTAATGAGCTTGCCATTCTT M13R-GGTAACTGCAGGTTACATAAAACTAACGA 270
Exon 7 M13F-TGATTTAGTTGAGACTTACGTGC M13R-TTTATGAGGACAGCACATTGC 398
Exon 8 M13F-TTTGTATTCTGTAAAATGAGATCTTT M13R-CTTTGCTTTTTAAAAATAACTACTG 253
Exon 9 M13F-TAGGATTTTGTCACTTTGTTCTG M13R-GTGTATAGGACAAAAGAATTATTCC 237
Exon 10 M13F-GGTAGTAGGTATTTATGGAATACTTTTTC M13R-GCATTTAGGGAATTAATAAAGGG 286
Exon 11 M13F-CATTGCTTCTAGTACACATTT M13R-CAGGTGACATTCAGAACATTA 231
Exon 12 M13F-TCAGTATTCCTGTGTACATTT M13R-TTACCCCCACAAAGCCCAA 359
Exon 13 M13F-GTAGCAGAAAGAAGTTTAAAATCTTGC M13R-GGACAGAGACATACATTTCTATCTTC 341
Exon 14 M13F-CCACATTTTATGTGATGGGAA M13R-GGTAGTAAGTTTCCCATTAC 385
Exon 15 M13F-TGCTGTCTCTTCTCATGCTG M13R-AGAAGCTAAGTTAAACTATG 299
Exon 16 M13F-ATTTTAATTACTAATGGGACATTC M13R-TTAAGTTGATAGCCCATGG 370
*Forward primers have M13F tail attached for sequencing: TGTAAAACGACGGCCAGT; Reverse primers have M13R tail attached for sequencing:
CAGGAAACAGCTATGACC
PCR products were sequenced using either the ABI PRISM
BigDye v3.1 or, less frequently, the ABI PRISM
dRhodamine Terminator Cycle Sequencing Ready Reaction
(Applied Biosystems, Foster City, USA) kits. The identified
DNA sequence alterations were confirmed by sequencing of
both DNA strands in two independent PCR products. The
mutation nomenclature used complies with the recommenda-
tions of DEN DUNNEN and ANTONARAKIS [17, 18], DEN
DUNNEN and PAALMAN [19] and the latest nomenclature up-
dates on www.hgvs.org/mutnomen. The sequence variations
were described in relation to cDNA reference sequence from
a primary sequence database (NCBI GenBank using RefSeq
NM_000249.2 and NM_000251.1 for MLH1 and MSH2, re-
spectively). The reference sequences AH003234.1 and
AH003235.1 were used for mutation mapping of intronic re-
gions of the MLH1 and MSH2 genes, respectively. The amino
acid changes were deduced from nucleotide alterations in re-
lation to a protein reference sequence from SWISS-PROT,
using ID: P40692 for MLH1 and ID: P43246 for the MSH2
protein.
RT-PCR analysis. Total RNA was extracted from periph-
eral blood using PAXgene Blood RNA Kit (Qiagen, Hilden,
Germany). RT-PCR was performed using OneStep RT-PCR
Kit (Qiagen, Hilden, Germany) with MLH1-specific primers
located in exons 5 and 11, respectively, as published previ-
ously [20]. The RT-PCR products were resolved on 1.5
agarose gels. Individual bands were excised, purified by
MinElute Extraction Kit (Qiagen, Hilden, Germany),
reamplified by a second identical PCR reaction using Pfu
DNA polymerase, then cloned into pUC18 and subsequently
sequenced.
Results and discussion
Clinical data and family histories
of the patients with identified germ-
line mutations are summarized in
Table 3. Six patients belonged to
families fulfilling the AC-I criteria
and one met the AC-II criteria.
Three patients complied with BG
and one with RBG. All but one in-
dex cases, had colon cancer. Only
patient IT/SK-15 had a tumor in the
rectum. Three patients presented
with additional cancers in extra-
colonic sites; two (SK7, SK12) had
endometrial and one (SK10) ovar-
ian cancer. Metachronous or syn-
chronous tumors were present in
four (SK7, SK12, SK17, SK19) and
two (SK9, SK10) cases, respec-
tively. Right-sided colon tumor lo-
calization was described in the
medical records of six patients
(SK7, SK8, SK9, SK11, SK12, SK19) and mucinous histo-
pathology was confirmed in two tumors (SK7, SK8).
Microsatellite instability and immunohistochemical analyses
of most of these tumors will be described elsewhere
[FRIDRICHOVA et al, manuscript in preparation], as part of a
study evaluating the efficacy of pre-screening methods for
HNPCC diagnosis in a large cohort of patients.
In the present study, we describe the alterations (Tab. 4)
found in 11 HNPCC families by DNA sequencing of the MLH1
and MSH2 genes. To our knowledge, seven of these alterations
have not been previously reported in the literature and are not
included in the database of International Society of Gastrointes-
tinal Hereditary Tumors (http://www.insight-group.org/) or in
the Human Gene Mutation Database [21].
Genetic changes in the MLH1 promoter appear to be rare
[22, 23]. We found a novel change, c.-269C>G, in two appar-
ently unrelated patients (SK-7 and SK-9). However, both pa-
tients carried also additional mutations in the same gene. The
first (SK-7) had an A>C change at position -2 of the splice
acceptor site upstream of exon 7 (c.546-2A>C). The muta-
tion would cause skipping of exon 7, resulting in an
out-of-frame deletion that would lead to a premature stop
codon and truncated protein (p.Arg182SerfsX187). This
change, coupled with the promoter mutation, was identified
in another affected family member and in 4 asymptomatic
relatives, while 5 other asymptomatic relatives carried nei-
ther alteration. This indicated that both mutations affected the
same allele. RT-PCR of exons 5-11 yielded the expected
536 bp fragment in addition to a shorter product of 493 bp. As
expected, the cloning and subsequent DNA sequencing of the
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Table 3. Clinical data and cancer family histories of the patients included in this study
ID Tumor localization(age at onset)




SK-7 colon (52), endometrium (55) 1st: C(33, 43, 48); C(45)
2nd: En(41); C(60); C(61); C(74)
AC-I
SK-8 colon (49) 1st: C(55); Br(50) RBG
SK-9 duplex in colon (34) 2nd: En(42); En(60); C(68) BG
SK-10 colon + ovary (42) 1st: C(33); C + En(32); C(33)
2nd: C; C(37); C + Ov(29); C(49); En(58); St(37)
AC-I
SK-11 colon (29) 1st: polyp at En(?)
2nd: En(?); M(59) + polyp in the colon (?); En(57)
BG
SK-12 endometrium (52), colon (53) 1st: C(57); En(45) + C(46) AC-I
SK-13 colon (30) 1st: duplex C(41); C(28)
2nd: C(40); C(?); C(61)
3rd: C(?)
AC-I
IT/SK-15 rectum (28) 1st: Br(37)
2nd: C(38); C(40); C(55); C(29); En(75)
AC-I
SK-17 colon (32, 47, 50) 1st: C(73) BG
SK-19 colon (32, 39, 54, 62) 1st: C(42)
2nd: En(50) + Br(48); En(50)
AC-II
SK-24 colon (42) 1st: C(32), C(27), C(39) AC-I
ID – patient/family ID number, C – colon, En – endometrium, St – stomach, Br – breast, Ov – ovary, M – ma-
lignant melanoma. Individuals are separated by a semicolon, (?): age at onset not known. AC-I/AC-II – Am-
sterdam criteria I, II; BG – Bethesda Guidelines; RBG – Revised Bethesda Guidelines.
shorter product showed that exon 6 was spliced directly onto
exon 8 (Fig. 1, left panel). This suggests that the skipping of
exon 7 represents the pathological mutation, as the promoter
mutation did not affect transcription from this allele. In the
second patient (SK-9) carrying the MLH1 promoter change, a
frameshift mutation c.1150delG in exon 12 of MLH1 was de-
tected in the germline. This change should lead to a truncated
protein p.Val384PhefsX400 and is very likely the primary
pathogenic mutation, even though we could not perform seg-
regation analysis in this family. Thus, although the promoter
change c.-269C>G was not present in 100 control chromo-
somes and does not seem to be a polymorphism, we assume
that it is not pathogenic.
Despite the fact that patient SK-8 fulfilled solely the least
stringent HNPCC criteria (RBG), she was included in the
mutational screening, as the presence of the mucinous
right-sided colon tumor was highly indicative of HNPCC. In-
terestingly, the identified mutation, c.210_213delAGAA,
was previously described in a Finnish family meeting the
strict AC-I criteria for HNPCC. This deletion, located three
nucleotides downstream from the 5’ end of MLH1 exon 3,
should lead to a frameshift and result in truncated protein
(p.Glu71IlefsX90). However, the authors showed that the
consequence at the RNA level is the skipping of exon 3 due to
disruption of a 5’ splice site [24]. Interestingly, in our family
the same mutation was identified also in three of the patient’s
nephews, suggesting that their mother, the proband’s sister,
was an obligate carrier. Unfortunately, this could not be con-
firmed, as she died at a relatively early age of breast cancer,
a tumor the inclusion of which in the HNPCC-tumor
spectrum is still controversial [25–29].
Patients SK-10 and SK-24 carried identical mutations at
the last nucleotide of MLH1 exon 8 (c.677G>T), which was
originally described in a Moldavian family [30]. This
transversion could be classified as a missense mutation
(p.Arg226Leu), however, its location at the 3’ splice site re-
gion may suggest skipping of exon 8. The same mutation was
previously found by our group in another Slovak family [1].
High frequency of this mutation in our and other populations
supports the hypothesis that exonic CpG dinucleotides in
MLH1 and MSH2 might be hotspots for recurrent HNPCC
mutations, which can be either of ancestral origin or derived
from de novo events.
Patient SK-11 presented with a right-sided colon cancer at
29 years of age. The transversion c.793C>A in exon 10 found
in the germline of this patient is a missense mutation, presum-
ably leading to a change from a positively-charged arginine
to a polar serine (p.Arg265Ser). A transition at the same posi-
tion c.793C>T, leading to a change of arginine to cysteine,
was found previously in a Czech family [31]. Another alter-
ation affecting the same codon (c.794G>A) and resulting in a
change from arginine to histidine was found in an Italian
HNPCC family. However, it was classified as a rare polymor-
phism (not found in 196 control chromosomes), as it co-seg-
regated with an additional mutation in the same gene, which
resulted in a frameshift [32]. Recent structural studies
showed that Arg265 corresponds to Arg261 of E. coli MutL,
which destabilizes the P loop if mutated to His. This mutation
reduces ATP binding and ATP-dependent activation of MutH
endonuclease [33, 34]. We thus assume that the mutation
found in patient SK-11 might have pathological conse-
quences. The alteration was not present in 100 control chro-
mosomes, but was detected in two other members of family
SK-11 presenting with endometrial and colonic polyps, re-
spectively. In addition, the colon cancer of the proband
lacked MLH1 in IHC analysis (unpublished data) and no ad-
ditional alterations were found in MLH1 or MSH2. Taken to-
gether, we suggest that the missense mutation c.793C>A in
exon 10 of MLH1 may predispose to HNPCC.
Patient SK-12 was diagnosed with endometrial cancer
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Table 4. Novel and reccurrent MLH1 and MLH2 germline alterations detected in the present study
ID Gene Region Nucleotide Change2 Consequences4 First description
SK-7 MLH1 promoter




r.546_588del (skipping of exon 7)
novel
novel
SK-8 MLH1 exon 3 c.210_213delAGAA splice defect (skipping of exon 3) Renkonen et al., 2004
SK-9 * MLH1 exon 12 c.1150delG p.Val384 PhefsX400 novel
SK-10 MLH1 exon 8 c.677G>T p.Arg226Leu + splice defect Maliaka et al., 1996
SK-11 MLH1 exon 10 c.793C>A3 p.Arg265Ser novel
SK-12 MLH1 exon 12 c.1210_1211delCT p.Leu404ValfsX415 novel










Maliaka et al., 1996
SK-17 MLH1 exon 10 c.883A>C3 r.791_884del (skipping of exon 10) Kurzawski et al., 2006
SK-19 MSH2 exon 7 c.1129C>T p.Gln377X novel
SK-24 MLH1 exon 8 c.677G>T p.Arg226Leu + splice defect Maliaka et al., 1996
*The patient carried also the same promoter change as patient SK-7; 1splice acceptor site; 2the changes were experimentally determined at DNA level, number-
ing is based on cDNA sequence, position +1 corresponds to the A of the ATG translation initiation codon in the RefSeq; 3the change was not found in 100 con-
trol chromosomes; 4the consequences at RNA level (r.) were experimentally determined, the consequences on the protein level (p.) are theoretically predicted.
aged 52 and with right-sided colon cancer a year later. A 2-bp
deletion (c.1210_1211delCT) in exon 12 of MLH1 was de-
tected. This mutation leads to a premature stop codon 33 nu-
cleotides downstream (codon 415 in exon 12). At the protein
level it results in a reading frame change starting at Leu404,
whereby the -2 open reading frame remains open for 10
amino acids. The truncated protein, if stable, will lack the in-
teraction domain of MLH1 with PMS2 [35].
In the genomic DNA of patient SK-13 we identified a tran-
sition mutation (c.350C>T) in exon 4 of MLH1, which was
previously described in other populations [30, 31, 36, 37,
38]. This mutation presumably leads to a non-conservative
amino acid change of a polar threonine to a hydrophobic
methionine (p.Thr117Met) in the highly-conserved region of
MLH1. The mutation segregated with two other affected
family members and IHC showed absence of MLH1 (unpub-
lished data). We therefore assume that the SK-13 mutation is
pathogenic.
Patient IT/SK-15 is of Italian origin with offspring living
in Slovakia. His family met the AC-I criteria and its germline
mutation was apparently linked to the maternal line of the pa-
tient. However, the mother died of breast cancer at the age of
37, which is not typically associated with HNPCC, as already
discussed. At first, we sequenced the MLH1 gene and ob-
served a variation c.381-41A>G in intron 4. Although this al-
teration was not present in 100 control chromosomes and
could not be classified as a polymorphism, we proceeded
with the sequencing of the MSH2 gene, where the change
c.1861C>T in exon 12 was detected. This latter change has
been described for the first time in Moldavia [30]. Since it is a
nonsense mutation and was found also in other HNPCC fam-
ilies from Western Europe and USA (unpublished data in the
InSIGHT database), its association with the disease in our pa-
tient is very likely, while the consequences of the MLH1
intronic change are not clear at this time. The frequent detec-
tion of the recurrent mutations c.350C>T in MLH1 and
c.1861C>T in MSH2 in different populations supports the
hypothesis that exonic CpG dinucleotides represent
mutational hotspots, as already mentioned for mutation
c.677G>T in MLH1.
Patient SK-17, who presented with three metachronous
colon cancers diagnosed at 32, 47 and 50 years of age, carried
the transversion c.883A>C in exon 10 of the MLH1 gene.
Since this mutation is located only two nucleotides upstream
from the highly-conserved “GT” dinucleotide of a splice do-
nor site, we performed RT-PCR analysis, which detected an
additional, shorter fragment suggesting aberrant splicing.
Cloning and subsequent sequencing of this fragment con-
firmed this; the deletion of 94 bp indicated that exon 9 was
spliced directly onto exon 11 (Fig. 1, right panel). This indi-
cates that deletion of exon 10 is pathogenic. The patient car-
ried also a common polymorphism (c.655A>G) in exon 8 and
the “G” allele co-segregated with the aberrantly-spliced al-
lele. During the preparation of this manuscript, the c.883A>C
mutation was found also in a HNPCC family from Poland
[39].
Patient SK-19 presented with four metachronous colon tu-
mors at 32, 39, 54 and 62 years of age. DNA sequencing re-
vealed a novel nonsense mutation localized in exon 7 of
MSH2 (c.1129C>T) leading to a change of glutamine at posi-
tion 377 to a premature stop codon. Interestingly, this was the
third family in our study (27%), in which occurrence of
breast cancer was reported in first or second degree relatives
at early age. This evidence supports attempts to include
breast cancer in the HNPCC tumor spectrum [26, 29].
In summary, 9 of 11 (82%) pathogenic germline mutations
detected in this study by direct genomic sequencing of the
MLH1 and MSH2 genes were located in the MLH1 gene. In
our previous mutation study, 4 of 6 (67%) pathogenic
germline mutations were also located in the MLH1 gene [1].
Taken together, this evidence suggests that most (13/17,
76%) point mutations and small deletions/insertions in Slo-
vak HNPCC families occur in the MLH1 gene. However,
germline mutations in the MSH2 gene are frequently large
deletions/insertions, which are not detectable by DNA se-
quencing [40–43]. In order to eliminate the possibility that
direct sequencing failed to identify the latter mutations, we
are currently deploying MLPA analysis, which is the pre-
ferred method for identification of large gene rearrangements
[44].
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Figure 1. Nucleotide sequence analysis of alternatively-spliced transcripts of the MLH1 gene. Left panel: splicing of exon 6 directly onto exon 8 in pa-
tient SK-7; Right panel: splicing of exon 9 directly onto exon 11 in patient SK-17.
Exon 6 Exon 8 Exon 9 Exon 11
The alterations in the MMR genes described in this study
were detected as part of a molecular screening program initi-
ated several years ago, the primary objective of which is to
identify all HNPCC families in Slovakia [1, 2]. Symptomatic
and asymptomatic MMR gene mutation carriers who take ad-
vantage of this predictive molecular-genetic analysis are fol-
lowed up with an annual colonoscopy, and, where appropri-
ate, with abdominal and transvaginal sonography. The
efficacy of this cancer prevention strategy is currently under
investigation.
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